DANONE (BSN.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:BSN • FR0000120644

69.2 EUR
-2.58 (-3.59%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to BSN. BSN was compared to 62 industry peers in the Food Products industry. BSN scores excellent on profitability, but there are concerns on its financial health. BSN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year BSN was profitable.
  • BSN had a positive operating cash flow in the past year.
  • Each year in the past 5 years BSN has been profitable.
  • In the past 5 years BSN always reported a positive cash flow from operatings.
BSN.DE Yearly Net Income VS EBIT VS OCF VS FCFBSN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

1.2 Ratios

  • The Return On Assets of BSN (4.20%) is better than 66.13% of its industry peers.
  • Looking at the Return On Equity, with a value of 11.59%, BSN is in the better half of the industry, outperforming 69.35% of the companies in the same industry.
  • BSN has a Return On Invested Capital of 6.83%. This is in the better half of the industry: BSN outperforms 66.13% of its industry peers.
  • BSN had an Average Return On Invested Capital over the past 3 years of 6.38%. This is in line with the industry average of 6.69%.
  • The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.2%
ROE 11.59%
ROIC 6.83%
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
BSN.DE Yearly ROA, ROE, ROICBSN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.72%, BSN is in the better half of the industry, outperforming 75.81% of the companies in the same industry.
  • BSN's Profit Margin has been stable in the last couple of years.
  • With an excellent Operating Margin value of 13.25%, BSN belongs to the best of the industry, outperforming 80.65% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BSN has declined.
  • BSN has a Gross Margin of 50.47%. This is amongst the best in the industry. BSN outperforms 83.87% of its industry peers.
  • In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
Industry RankSector Rank
OM 13.25%
PM (TTM) 6.72%
GM 50.47%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
BSN.DE Yearly Profit, Operating, Gross MarginsBSN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
  • Compared to 1 year ago, BSN has more shares outstanding
  • BSN has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BSN has an improved debt to assets ratio.
BSN.DE Yearly Shares OutstandingBSN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
BSN.DE Yearly Total Debt VS Total AssetsBSN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.2 Solvency

  • BSN has an Altman-Z score of 2.43. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BSN has a Altman-Z score (2.43) which is in line with its industry peers.
  • BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 5.07, BSN is in the better half of the industry, outperforming 72.58% of the companies in the same industry.
  • BSN has a Debt/Equity ratio of 0.83. This is a neutral value indicating BSN is somewhat dependend on debt financing.
  • BSN has a worse Debt to Equity ratio (0.83) than 69.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF 5.07
Altman-Z 2.43
ROIC/WACC1.07
WACC6.4%
BSN.DE Yearly LT Debt VS Equity VS FCFBSN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
  • BSN's Current ratio of 0.95 is on the low side compared to the rest of the industry. BSN is outperformed by 70.97% of its industry peers.
  • BSN has a Quick Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BSN has a Quick ratio of 0.78. This is comparable to the rest of the industry: BSN outperforms 43.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.78
BSN.DE Yearly Current Assets VS Current LiabilitesBSN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.47% over the past year.
  • Measured over the past years, BSN shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.17% on average per year.
  • Looking at the last year, BSN shows a small growth in Revenue. The Revenue has grown by 0.54% in the last year.
  • BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.60% yearly.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%

3.2 Future

  • BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.09% yearly.
  • Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 2.86% on average per year.
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.09%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BSN.DE Yearly Revenue VS EstimatesBSN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 10B 20B 30B
BSN.DE Yearly EPS VS EstimatesBSN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • BSN is valuated rather expensively with a Price/Earnings ratio of 18.50.
  • The rest of the industry has a similar Price/Earnings ratio as BSN.
  • The average S&P500 Price/Earnings ratio is at 28.06. BSN is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 16.60, which indicates a correct valuation of BSN.
  • BSN's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 27.86. BSN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 18.5
Fwd PE 16.6
BSN.DE Price Earnings VS Forward Price EarningsBSN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
  • BSN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BSN is cheaper than 69.35% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.44
EV/EBITDA 9.97
BSN.DE Per share dataBSN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.46
PEG (5Y)N/A
EPS Next 2Y7.18%
EPS Next 3Y7.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • BSN has a Yearly Dividend Yield of 2.99%.
  • BSN's Dividend Yield is a higher than the industry average which is at 3.02.
  • BSN's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 2.99%

5.2 History

  • The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
BSN.DE Yearly Dividends per shareBSN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

  • 74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
  • BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
BSN.DE Yearly Income VS Free CF VS DividendBSN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
BSN.DE Dividend Payout.BSN.DE Dividend Payout, showing the Payout Ratio.BSN.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

DANONE

FRA:BSN (2/6/2026, 7:00:00 PM)

69.2

-2.58 (-3.59%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)10-07
Earnings (Next)02-20
Inst Owners54.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap47.15B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts75.33
Price Target80.67 (16.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.99%
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.23%
PT rev (3m)1.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.43%
EPS NY rev (3m)-0.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE 18.5
Fwd PE 16.6
P/S 1.72
P/FCF 16.44
P/OCF 12.26
P/B 2.97
P/tB N/A
EV/EBITDA 9.97
EPS(TTM)3.74
EY5.4%
EPS(NY)4.17
Fwd EY6.03%
FCF(TTM)4.21
FCFY6.08%
OCF(TTM)5.64
OCFY8.16%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.46
PEG (5Y)N/A
Graham Number44.26
Profitability
Industry RankSector Rank
ROA 4.2%
ROE 11.59%
ROCE 12.02%
ROIC 6.83%
ROICexc 8.36%
ROICexgc 50.58%
OM 13.25%
PM (TTM) 6.72%
GM 50.47%
FCFM 10.49%
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF 5.07
Debt/EBITDA 2.71
Cap/Depr 77.72%
Cap/Sales 3.57%
Interest Coverage 23.53
Cash Conversion 78.8%
Profit Quality 156.01%
Current Ratio 0.95
Quick Ratio 0.78
Altman-Z 2.43
F-Score8
WACC6.4%
ROIC/WACC1.07
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.09%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.93%
EBIT Next 3Y14.73%
EBIT Next 5Y10.6%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%

DANONE / BSN.DE FAQ

What is the fundamental rating for BSN stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.


What is the valuation status for BSN stock?

ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.


How profitable is DANONE (BSN.DE) stock?

DANONE (BSN.DE) has a profitability rating of 7 / 10.


What is the earnings growth outlook for DANONE?

The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.53% in the next year.


Is the dividend of DANONE sustainable?

The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 74.99%.